List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7189151/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Realâ€World Six―and Twelveâ€Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care and Research, 2022, 74, 1205-1218.	3.4	20
2	Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data. European Journal of Health Economics, 2022, 23, 1357-1369.	2.8	1
3	Lessons from experiences of accessing healthcare during the pandemic for remobilizing rheumatology services: a national mixed methods study. Rheumatology Advances in Practice, 2022, 6, rkac013.	0.7	0
4	Enabling work participation for people with musculoskeletal conditions: lessons from work changes imposed by COVID-19: a mixed-method study. BMJ Open, 2022, 12, e057919.	1.9	1
5	European bio-naÃ⁻ve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology, 2022, 61, 3799-3807.	1.9	7
6	P178 Advising workers with distal arm pain to remain active: a secondary analysis of the ARM trial, a multicentre randomised controlled trial. Rheumatology, 2022, 61, .	1.9	0
7	P272 Pregnancy outcomes in women receiving biological therapy for axial spondyloarthritis. Rheumatology, 2022, 61, .	1.9	0
8	P262 The occurrence and characteristics of severe pain in patients with axial spondyloarthritis. Rheumatology, 2022, 61, .	1.9	0
9	OA17 The risk of inflammatory bowel disease in patients with axial spondyloarthritis treated with biologic agents: data from the BSR registry in axial spondyloarthritis (BSRBR-AS) and meta-analysis. Rheumatology, 2022, 61, .	1.9	0
10	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology, 2022, 61, e255-e266.	1.9	6
11	Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. Rheumatology, 2021, 60, 3189-3198.	1.9	12
12	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology, 2021, 60, 1588-1592.	1.9	4
13	The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis. Rheumatology, 2021, 60, 4121-4129.	1.9	7
14	P155â€88000 faecal calprotectin measurements over 15 years: insights gained from the edinburgh faecal calprotectin register. , 2021, , .		0
15	Simplified bedside assessment of pulmonary gas exchange in very preterm infants at 36 weeks' postmenstrual age. Thorax, 2021, 76, 689-695.	5.6	6
16	Maintaining musculoskeletal health using a behavioural therapy approach: a population-based randomised controlled trial (the MAmMOTH Study). Annals of the Rheumatic Diseases, 2021, 80, 903-911.	0.9	10
17	Epidemiology of chronic pain in children and adolescents: a protocol for a systematic review update. BMJ Open, 2021, 11, e043675.	1.9	13
18	Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology, 2021, 60, 5734-5742.	1.9	9

#	Article	IF	CITATIONS
19	Driving difficulties in patients with axial spondyloarthritis: Results from the Scotland Registry for Ankylosing Spondylitis. Arthritis Care and Research, 2021, , .	3.4	3
20	Realâ€world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2067-2075.	2.8	17
21	The effect of COVID-19 public health restrictions on the health of people with musculoskeletal conditions and symptoms: the CONTAIN study. Rheumatology, 2021, 60, SI13-SI24.	1.9	10
22	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2021, 80, 1168-1174.	0.9	49
23	The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register. BMC Rheumatology, 2021, 5, 19.	1.6	2
24	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2021, 80, 1410-1418.	0.9	28
25	Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. Rheumatology, 2021, 60, 5795-5800.	1.9	10
26	Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. Rheumatology, 2021, 60, 4158-4165.	1.9	8
27	Impact of Smoking in Response to Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Methodologic Considerations for Longitudinal Observational Studies. Arthritis Care and Research, 2020, 72, 591-599.	3.4	14
28	Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS). Annals of the Rheumatic Diseases, 2020, 79, 202-208.	0.9	42
29	BRITSpA at five. Rheumatology, 2020, 59, 699-701.	1.9	0
30	P244 Determining factors related to poor quality of life in patients with axSpA: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2020, 59, .	1.9	0
31	P246 Predicting non-response to biologic therapy amongst patients with axSpA: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2020, 59, .	1.9	0
32	P257 Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?. Rheumatology, 2020, 59, .	1.9	0
33	The role of metrology in axSpA: does it provide unique information in assessing patients and predicting outcome? Results from the BSRBRâ€AS registry. Arthritis Care and Research, 2020, , .	3.4	3
34	Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?. Annals of the Rheumatic Diseases, 2020, 79, 914-919.	0.9	10
35	What is the incidence of complex regional pain syndrome (CRPS) Type I within four months of a wrist fracture in the adult population? A systematic review. Hand Therapy, 2020, 25, 45-55.	1.4	6
36	The prevalence of fibromyalgia in axial spondyloarthritis. Rheumatology International, 2020, 40, 1581-1591.	3.0	28

#	Article	IF	CITATIONS
37	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. , 2020, 61, 3.		43
38	Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. RMD Open, 2020, 6, e001206.	3.8	11
39	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14Â868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	1.9	7
40	The epidemiology of regular opioid use and its association with mortality: Prospective cohort study of 466 486 UK biobank participants. EClinicalMedicine, 2020, 21, 100321.	7.1	29
41	Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. Rheumatology, 2020, 59, 3408-3414.	1.9	6
42	Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology, 2020, 59, 2481-2490.	1.9	24
43	Cost-utility of maintained physical activity and physiotherapy in the management of distal arm pain: an economic evaluation of data from a randomized controlled trial. Family Practice, 2019, 36, 179-186.	1.9	3
44	Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 177.	3.5	5
45	Investigating the role of beliefs about emotions, emotional suppression and distress within a pain management programme for fibromyalgia. British Journal of Pain, 2019, 13, 112-120.	1.5	5
46	O2O The impact of axial spondyloarthritis on work productivity in individuals living in rural areas: results from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS). Rheumatology, 2019, 58, .	1.9	0
47	Treatment response and drug retention rates in 24 195 biologic-naÃ ⁻ ve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2019, 78, 1536-1544.	0.9	58
48	AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). BMC Rheumatology, 2019, 3, 19.	1.6	10
49	Psychological therapies for chronic widespread pain and fibromyalgia syndrome. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101416.	3.3	12
50	Maintained physical activity and physiotherapy in the management of distal arm pain: a randomised controlled trial. RMD Open, 2019, 5, e000810.	3.8	6
51	Smoking does not protect patients with axial spondyloarthritis from attacks of uveitis. Annals of the Rheumatic Diseases, 2019, 78, 1287-1288.	0.9	5
52	OP0262â€FACTORS ASSOCIATED WITH ACUTE ANTERIOR UVEITIS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: ANALYSIS OF THE BSRBR-AS REGISTER DATABASE. , 2019, , .		1
53	OP0233â€THE IMPACT OF EXTRA-ARTICULAR MANIFESTATIONS ON THE CHOICE OF TNF INHIBITOR IN PATIEN WITH AXIAL SPONDYLOARTHRITIS IN THE BSRBR-AS REGISTER. , 2019, , .	TS	0
54	Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS). Rheumatology, 2019, 58, 811-819.	1.9	21

#	Article	IF	CITATIONS
55	Identifying Persons with Axial Spondyloarthritis At Risk of Poor Work Outcome: Results from the British Society for Rheumatology Biologics Register. Journal of Rheumatology, 2019, 46, 145-152.	2.0	31
56	Dimension of pain-related quality of life and self-reported mental health in men and women of the European Prospective Investigation into Cancer–Norfolk cohort: a population-based cross-sectional study. British Journal of Pain, 2018, 12, 35-46.	1.5	0
57	Five Potentially Modifiable Factors Predict Poor Quality of Life in Ankylosing Spondylitis: Results from the Scotland Registry for Ankylosing Spondylitis. Journal of Rheumatology, 2018, 45, 62-69.	2.0	27
58	O01 Do patients with axial spondyloarthritis who meet research criteria for fibromyalgia benefit from biologic therapy?. Rheumatology, 2018, 57, .	1.9	0
59	PTU-002â€Achieving biochemical remission in crohn's disease with adalimumab therapy utilsing therapeutic drug monitoring. , 2018, , .		0
60	iO84â \in fThe BSRBR-PsA: plans and progress. Rheumatology, 2018, 57, .	1.9	0
61	186 Quality of life estimation in economic evaluations and healthcare decision making: different approaches, different results. Results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS). Rheumatology, 2018, 57, .	1.9	0
62	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. Rheumatology, 2018, 57, 1982-1990.	1.9	26
63	Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis. Annals of the Rheumatic Diseases, 2018, 77, 1578-1584.	0.9	39
64	K2â€∫Impact of biologic therapy on work in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) and meta-analysis. Rheumatology, 2018, 57, .	1.9	0
65	Impact of Moving From a Widespread to Multisite Pain Definition on Other Fibromyalgia Symptoms. Arthritis Care and Research, 2017, 69, 1878-1886.	3.4	12
66	EULAR recommendations for management of fibromyalgia. Annals of the Rheumatic Diseases, 2017, 76, e54-e54.	0.9	33
67	Disease Severity in Never Smokers, Ex‣mokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis. Arthritis Care and Research, 2017, 69, 1407-1413.	3.4	26
68	Coâ€Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia. Arthritis and Rheumatology, 2017, 69, 2144-2150.	5.6	59
69	Investigating generalizability of results from a randomized controlled trial of the management of chronic widespread pain: the MUSICIAN study. Pain, 2017, 158, 96-102.	4.2	12
70	Persons with chronic widespread pain experience excess mortality: longitudinal results from UK Biobank and meta-analysis. Annals of the Rheumatic Diseases, 2017, 76, 1815-1822.	0.9	116
71	BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing) Tj ETQq1 1 0.784314	⊦rgBT /Ov	erlock 10 Tf 5
72	SPONDYLARTHROPATHIES (INCLUDING PSORIATIC ARTHRITIS)099.â€∱SMOKING EXPOSURE IS ASSOCIATED W INCREASED DISEASE SEVERITY IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR	/ITH 1.9	0

RHEUMATOLOGY BIOLOGICS REGISTER FOR ANKYLOSING SPONDYLITIS. Rheumatology, 2017, 56, .

#	Article	IF	CITATIONS
73	Identification and Validation of Clinically Relevant Clusters of Severe Fatigue in Rheumatoid Arthritis. Psychosomatic Medicine, 2017, 79, 1051-1058.	2.0	13
74	Differences in the prevalence of ankylosing spondylitis in primary and secondary care: only one-third of patients are managed in rheumatology. Rheumatology, 2016, 55, 1820-1825.	1.9	18
75	Constructs of health belief and disabling distal upper limb pain. Scandinavian Journal of Pain, 2016, 13, 91-97.	1.3	2
76	The Maintaining Musculoskeletal Health (MAmMOTH) Study: Protocol for a randomised trial of cognitive behavioural therapy versus usual care for the prevention of chronic widespread pain. BMC Musculoskeletal Disorders, 2016, 17, 179.	1.9	10
77	Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2016, 55, 1786-1790.	1.9	74
78	Chronic widespread bodily pain is increased among individuals with history of fracture: findings from UK Biobank. Archives of Osteoporosis, 2016, 11, 1.	2.4	26
79	Examining Changes in Central and Peripheral Pain as Mediates of Fatigue Improvement: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 922-926.	3.4	12
80	Psychosocial Vulnerability and Early Life Adversity as Risk Factors for Central Sensitivity Syndromes. Current Rheumatology Reviews, 2016, 12, 140-153.	0.8	33
81	The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment. BMC Musculoskeletal Disorders, 2015, 16, 347.	1.9	39
82	Establishing the characteristics for patients with chronic Complex Regional Pain Syndrome: the value of the CRPS-UK Registry. British Journal of Pain, 2015, 9, 122-128.	1.5	27
83	The epidemiology of regional and widespread musculoskeletal pain in rural versus urban settings in those ≥55 years. British Journal of Pain, 2015, 9, 86-95.	1.5	16
84	A systematic review of prognostic factors for distal upper limb pain. British Journal of Pain, 2015, 9, 241-255.	1.5	10
85	Determining Pathways to Improvements in Fatigue in Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2303-2310.	5.6	46
86	Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2015, 54, 964-971.	1.9	58
87	Normative data for the Hospital Anxiety and Depression Scale. Quality of Life Research, 2015, 24, 391-398.	3.1	135
88	Risk of recurrent stillbirth: systematic review and meta-analysis. BMJ, The, 2015, 350, h3080-h3080.	6.0	153
89	Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review. Seminars in Arthritis and Rheumatism, 2015, 45, 238-250.	3.4	26
90	The Longitudinal Course of Fatigue in Rheumatoid Arthritis: Results from the Norfolk Arthritis Register. Journal of Rheumatology, 2015, 42, 2059-2065.	2.0	35

#	Article	IF	CITATIONS
91	The re-evaluation of the measurement of pain in population-based epidemiological studies: The SHAMA study. British Journal of Pain, 2015, 9, 134-141.	1.5	6
92	Can large surveys conducted on highly selected populations provide valid information on the epidemiology of common health conditions? An analysis of UK Biobank data on musculoskeletal pain. British Journal of Pain, 2015, 9, 203-212.	1.5	53
93	The Prevalence of Fibromyalgia in the General Population: A Comparison of the American College of Rheumatology 1990, 2010, and Modified 2010 Classification Criteria. Arthritis and Rheumatology, 2015, 67, 568-575.	5.6	323
94	230.â€∱Predictors of Driving Disability in Ankylosing Spondylitis: Results from the Scotland and Ireland Registry for Ankylosing Spondylitis. Rheumatology, 2014, 53, i145-i146.	1.9	0
95	225. Determinants of As-Related Fatigue and the Risks of its Persistence: Results from the Scotland and Ireland Registry for Ankylosing Spondylitis. Rheumatology, 2014, 53, i144-i144.	1.9	0
96	Neural correlates of fatigue in granulomatosis with polyangiitis: a functional magnetic resonance imaging study. Rheumatology, 2014, 53, 2080-2087.	1.9	19
97	Current Evidence of Anti–Tumor Necrosis Factor α Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Metaâ€Analysis Approach of Individual Drugs. Arthritis Care and Research, 2014, 66, 1073-1084.	3.4	98
98	The effect of an internet option and single-sided printing format to increase the response rate to a population-based study: a randomized controlled trial. BMC Medical Research Methodology, 2014, 14, 104.	3.1	8
99	Trauma and Fibromyalgia — Black and White? Or 50 Shades of Grey?. Journal of Rheumatology, 2014, 41, 1732-1733.	2.0	3
100	The characterisation and determinants of quality of life in ANCA associated vasculitis. Annals of the Rheumatic Diseases, 2014, 73, 207-211.	0.9	74
101	Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: The evidence from a systematic review and meta-analysis approach. Seminars in Arthritis and Rheumatism, 2014, 44, 39-46.	3.4	27
102	Global prevalence of ankylosing spondylitis. Rheumatology, 2014, 53, 650-657.	1.9	490
103	Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology, 2014, 53, 953-956.	1.9	38
104	HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	21.4	165
105	Maintained physical activity and physiotherapy in the management of distal upper limb pain – a protocol for a randomised controlled trial (the arm pain trial). BMC Musculoskeletal Disorders, 2014, 15, 71.	1.9	6
106	224. The Natural History of Ankylosing Spondylitis: Results from the Scotland and Ireland Registry for Ankylosing Spondylitis. Rheumatology, 2014, 53, i143-i144.	1.9	2
107	Pain reporting in older adults: the influence of cognitive impairment – results from the Cambridge City >75 Cohort study. British Journal of Pain, 2014, 8, 119-124.	1.5	7
108	Fatigue-related brain white matter changes in granulomatosis with polyangiitis. Rheumatology, 2013, 52, 1429-1434.	1.9	8

#	Article	IF	CITATIONS
109	Explaining fatigue in ANCA-associated vasculitis. Rheumatology, 2013, 52, 1680-1685.	1.9	50
110	Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology, 2013, 52, 825-831.	1.9	116
111	Alternative population sampling frames produced important differences in estimates of association: a case–control study of vasculitis. Journal of Clinical Epidemiology, 2013, 66, 675-680.	5.0	3
112	Environmental risk factors in systemic sclerosis. Current Opinion in Rheumatology, 2013, 25, 179-183.	4.3	35
113	Genome-wide association study meta-analysis of chronic widespread pain: evidence for involvement of the Sp15.2 region. Annals of the Rheumatic Diseases, 2013, 72, 427-436.	0.9	112
114	Reproducibility of pain manikins: a comparison of paper versus online questionnaires. British Journal of Pain, 2013, 7, 130-137.	1.5	5
115	A systematic review of evidence for the effectiveness of practitioner-based complementary and alternative therapies in the management of rheumatic diseases: osteoarthritis. Rheumatology, 2012, 51, 2224-2233.	1.9	32
116	Challenges in the management of distal arm pain. Pain Management, 2012, 2, 97-100.	1.5	1
117	The evidence base for managing older persons with low back pain. British Journal of Pain, 2012, 6, 166-169.	1.5	8
118	A systematic review of evidence for the effectiveness of practitioner-based complementary and alternative therapies in the management of rheumatic diseases: rheumatoid arthritis. Rheumatology, 2012, 51, 1707-1713.	1.9	50
119	Is there an association between preterm birth or low birthweight and chronic widespread pain? Results from the 1958 <scp>B</scp> irth Cohort Study. European Journal of Pain, 2012, 16, 134-139.	2.8	24
120	The prevalence and management of low back pain across adulthood: Results from a population-based cross-sectional study (the MUSICIAN study). Pain, 2012, 153, 27-32.	4.2	122
121	Diet, Lifestyle and Chronic Widespread Pain: Results from the 1958 British Birth Cohort Study. Pain Research and Management, 2011, 16, 87-92.	1.8	63
122	Pain in children – a call for more longitudinal research. Pain, 2011, 152, 2202-2203.	4.2	8
123	Role of road traffic accidents and other traumatic events in the onset of chronic widespread pain: Results from a populationâ€based prospective study. Arthritis Care and Research, 2011, 63, 696-701.	3.4	46
124	Epidemiology of back pain in older adults: prevalence and risk factors for back pain onset. Rheumatology, 2011, 50, 1645-1653.	1.9	129
125	The relationship between body mass index across the life course and knee pain in adulthood: results from the 1958 birth cohort study. Rheumatology, 2011, 50, 2251-2256.	1.9	38
126	Genetic variation in the beta2-adrenergic receptor but not catecholamine- O -methyltransferase predisposes to chronic pain: Results from the 1958 British Birth Cohort Study. Pain, 2010, 149, 143-151.	4.2	88

#	Article	IF	CITATIONS
127	Whether the weather influences pain? Results from the EpiFunD study in North West England. Rheumatology, 2010, 49, 1513-1520.	1.9	25
128	Influence of childhood behaviour on the reporting of chronic widespread pain in adulthood: results from the 1958 British Birth Cohort Study. Rheumatology, 2010, 49, 1882-1888.	1.9	32
129	Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology, 2010, 49, 1383-1390.	1.9	61
130	Musculoskeletal healthhow early does it start?. Rheumatology, 2009, 48, 1181-1182.	1.9	10
131	What Characterizes Persons Who Do Not Report Musculoskeletal Pain? Results from a 4-year Population-based Longitudinal Study (The Epifund Study). Journal of Rheumatology, 2009, 36, 1071-1077.	2.0	35
132	Predicting persistent low back pain in schoolchildren: A prospective cohort study. Arthritis and Rheumatism, 2009, 61, 1359-1366.	6.7	62
133	Adverse events in childhood and chronic widespread pain in adult life: Results from the 1958 British Birth Cohort Study. Pain, 2009, 143, 92-96.	4.2	229
134	Physical activity and emotional problems amongst adolescents. Social Psychiatry and Psychiatric Epidemiology, 2008, 43, 765-772.	3.1	74
135	Genetic and environmental influences on non-specific low back pain in children: a twin study. European Spine Journal, 2008, 17, 502-508.	2.2	67
136	The psychological and psychosocial impact of the Pakistan Kashmir earthquake after 8 months: a preliminary evaluation by PACTT. International Psychiatry: Bulletin of the Board of International Affairs of the Royal College of Psychiatrists, 2008, 5, 43-46.	0.1	3
137	The psychological and psychosocial impact of the Pakistan Kashmir earthquake after 8 months: a preliminary evaluation by PACTT. International Psychiatry: Bulletin of the Board of International Affairs of the Royal College of Psychiatrists, 2008, 5, 43-46.	0.1	0
138	Predicting the onset of knee pain: results from a 2-year prospective study of new workers. Annals of the Rheumatic Diseases, 2007, 66, 400-406.	0.9	31
139	Active Exercise, Education, and Cognitive Behavioral Therapy for Persistent Disabling Low Back Pain. Spine, 2007, 32, 1578-1585.	2.0	169
140	Are common symptoms in childhood associated with chronic widespread body pain in adulthood?: Results from the 1958 british birth cohort study. Arthritis and Rheumatism, 2007, 56, 1669-1675.	6.7	78
141	EpidemiologÃa del dolor. , 2007, , 1231-1246.		0
142	Managing low back pain presenting to primary care: Where do we go from here?. Pain, 2006, 122, 219-222.	4.2	48
143	Does physical trauma lead to an increase in the risk of new onset widespread pain?. Annals of the Rheumatic Diseases, 2006, 65, 391-393.	0.9	16
144	Epidemiology of pain. , 2006, , 1199-1214.		59

Epidemiology of pain. , 2006, , 1199-1214. 144

#	Article	IF	CITATIONS
145	Predicting persistent disabling low back pain in general practice: a prospective cohort study. British Journal of General Practice, 2006, 56, 334-41.	1.4	54
146	Predicting new onset of widespread pain following a motor vehicle collision. Journal of Rheumatology, 2006, 33, 968-74.	2.0	49
147	Comment on Hendriks et al.: Prognostic factors for poor recovery in acute whiplash patients. Pain 2005;114:408–416. Pain, 2005, 119, 247-248.	4.2	4
148	Onset of neck pain after a motor vehicle accident: a case-control study. Journal of Rheumatology, 2005, 32, 1576-83.	2.0	8
149	Predicting the onset of widespread body pain among children. Arthritis and Rheumatism, 2003, 48, 2615-2621.	6.7	72
150	Occurrence of Raynaud's phenomenon in children ages 12-15 years: Prevalence and association with other common symptoms. Arthritis and Rheumatism, 2003, 48, 3518-3521.	6.7	39
151	Risk factors for the onset of abdominal pain in children: A prospective population based study. Gastroenterology, 2003, 124, A18.	1.3	0
152	Predictors of Low Back Pain in British Schoolchildren: A Population-Based Prospective Cohort Study. Pediatrics, 2003, 111, 822-828.	2.1	239
153	Low back pain in schoolchildren: occurrence and characteristics. Pain, 2002, 97, 87-92.	4.2	275